Daewoong Pharmaceutical has announced tighter distribution controls for Nabota following detection of unauthorized exports of domestically-approved product. The move signals supply-chain leakage into gray markets—a recurring challenge for manufacturers with regional regulatory approvals and price differentials across geographies.
Gray-market botulinum toxin typically flows from lower-priced markets (Korea, India) to higher-priced ones (Middle East, Europe, North America), undercutting official distributors and creating liability for practices that unknowingly source compromised product. Daewoong's response—enhanced distributor vetting, serialization, and likely stricter contractual enforcement—is standard but often incomplete without end-user compliance.